To hardest-to-treat patients, Sanofi's Praluent looks cheap

Payers may already be cooking up ways to reduce the $14,600 yearly price of Sanofi ($SNY) and Regeneron's ($REGN) new PCSK9 drug, Praluent. But to some patients, the drug is a bargain. Those with rare condition heterozygous familial hypercholesterolemia, or FH, can't get their cholesterol levels down to normal with cheaper statins, and insurance companies have set a high bar for covering apheresis--a treatment that can run them $8,000 a month. The question now, The New York Times notes, is whether Praluent's arrival will shed light on the condition and spur doctors to treat it with PCSK9 drugs--and if they do, what it will do to U.S. drug spending. Story | More

Suggested Articles

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

A lawsuit says J&J helped doctors set up high-volume "infusion suites" and offered other services as kickbacks to amp up Remicade and Simponi…

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.